Voyager Therapeutics Stock News

Accomplished drug developer to help further long-term strategy, external scientific and business collaborations Robin Swartz promoted to chief operating officer CAMBRIDGE, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR ), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) technologies, today announced the appointment of Alfred W. Sandrock, Jr., M.D., Ph.D. to its Board of Directors, effective February 7, and a newly formed Executive Committee of the Board consisting of Dr. Sandrock, Michael Higgins, interim chief executive officer and Board Chairman, and Glenn Pierce, M.D., Ph.D., interim chief scientific officer and Board member. Dr. Sandrock will work with Voyager leadership to help shape future strategies for the Company''s next-generation TRACER TM AAV capsid screening platform and therapeutic programs, and expand its external collaborations with scientific leaders and industry partners. The Company also announced the promotion of Robin Swartz to chief operating officer, effective February 7.

Vertex (VRTX) delivered earnings and revenue surprises of 2.74% and 4.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Wall Street analysts expect Voyager Therapeutics, Inc. (NASDAQ:VYGR) to post earnings per share of ($0.21) for the current quarter, according to Zacks. Two analysts have issued estimates for Voyager Therapeutics earnings, with the highest EPS estimate coming in at $0.09 and the lowest estimate coming in at ($0.66). Voyager Therapeutics posted earnings of ($0.43) per []

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) have earned an average rating of Hold from the twelve brokerages that are currently covering the stock, Marketbeat.com reports. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year target price among brokerages []

Voyager Therapeutics, Inc. (NASDAQ:VYGR) has been assigned a consensus rating of Hold from the twelve research firms that are currently covering the stock, Marketbeat.com reports. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month target price among brokerages []

Voyager Therapeutics, Inc. (VYGR) with the stream of -0.98% also noticed, India Kelso Technologies Inc. (KIQ) encountered a rapid change of -1.12% in the last hour of Mondays trading session. The post Sizzling Stock Update: Voyager Therapeutics, Inc. (NASDAQ:VYGR), Kelso Technologies Inc. (AMEX:KIQ) appeared first on Stocks Equity .

CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Verve Therapeutics , Inc., (Nasdaq: VERV), a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Allison Dorval has been appointed as chief financial officer. Ms. Dorval joins Verve from Voyager Therapeutics and brings more than 20 years of leadership experience in finance, accounting, financial reporting and investor relations.

Equities analysts expect Voyager Therapeutics, Inc. (NASDAQ:VYGR) to announce ($0.26) earnings per share (EPS) for the current quarter, according to Zacks. Two analysts have made estimates for Voyager Therapeutics earnings. The lowest EPS estimate is ($0.66) and the highest is $0.09. Voyager Therapeutics posted earnings per share of ($0.43) in the same quarter last year, []

Brokerages expect that Voyager Therapeutics, Inc. (NASDAQ:VYGR) will report sales of $31.45 million for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Voyager Therapeutics earnings, with the lowest sales estimate coming in at $30.39 million and the highest estimate coming in at $32.50 million. Voyager Therapeutics posted sales of $6.54 [] The post Analysts Anticipate Voyager Therapeutics, Inc. (NASDAQ:VYGR) Will Post Quarterly Sales of $31.45 Million appeared first on ETF Daily News .

Xeris Biopharma Holdings, Inc. (XERS) with the stream of -0.91% also noticed, India Voyager Therapeutics, Inc. (VYGR) encountered a rapid change of -5.26% in the last hour of Friday’s trading … The post Stock Buzzers: Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), Voyager Therapeutics, Inc. (NASDAQ:VYGR) appeared first on Stocks Equity .

In the last trading session, 1.07 million shares of the Voyager Therapeutics Inc. (NASDAQ:VYGR) were traded, and its beta was 1.19. Most recently the companys share price was $3.29, and it changed around $0.13 or 4.11% from the last close, which brings the market valuation of the company to $119.89M. VYGR currently trades at a Why Voyager Therapeutics Inc. (NASDAQ: VYGR) Is A Stock Not To Be Discarded In 2021 Read More »

Voyager Therapeutics, Inc. (NASDAQ:VYGR) was the recipient of a significant decrease in short interest in October. As of October 29th, there was short interest totalling 2,400,000 shares, a decrease of 24.5% from the October 14th total of 3,180,000 shares. Approximately 9.3% of the shares of the company are short sold. Based on an average trading []

After making a strategic shift and losing its CEO on the way, VYGR is back with a new platform and a new big pharma deal.This time could be different, but we are sure we thought so last time, too.

Voyager Therapeutics, Inc. (NASDAQ:VYGR) was the target of a large drop in short interest during the month of October. As of October 29th, there was short interest totalling 2,400,000 shares, a drop of 24.5% from the October 14th total of 3,180,000 shares. Currently, 9.3% of the companys stock are short sold. Based on an average []

Novel intravenous (IV) vectorized antibody approach designed to activate innate immune system, destroy metastatic breast cancer tumors, and inhibit tumor progression in CNS